Clinical trial researchers struggle to recruit diverse patient populations, limiting medical research validity and perpetuating healthcare disparities

Medical researchers and pharmaceutical companies face critical barriers in enrolling Black and other underrepresented racial groups in clinical trials, resulting in medications and treatments tested primarily on white populations. This creates a vicious cycle where minorities distrust clinical trials due to historical medical racism, researchers can't meet diversity quotas, and treatments end up being less effective or safe for non-white patients. Current recruitment strategies fail because they don't address deep-rooted community skepticism or lack culturally competent outreach.